1 / 18

Chapter 21

Chapter 21. Antiarrhythmic Agents. Drug Overview. Class I IA: quinidine, procainamide IB: lidocaine, mexiletine, tocainide IC: flecainide, propafenone Class II β -Adrenergic blockers: propranolol, acebutolol. Drug Overview. Class III amiodarone, sotalol, ibutilide, dofetilide

jpowers
Download Presentation

Chapter 21

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 21 Antiarrhythmic Agents

  2. Drug Overview • Class I • IA: quinidine, procainamide • IB: lidocaine, mexiletine, tocainide • IC: flecainide, propafenone • Class II • β-Adrenergic blockers: propranolol, acebutolol

  3. Drug Overview • Class III • amiodarone, sotalol, ibutilide, dofetilide • Class IV • Calcium channel blockers: verapamil, diltiazem • Other • digoxin, adenosine

  4. Indications • Paroxysmal Supraventricular Tachycardia • Atrial Fibrillation • Premature Ventricular Contractions

  5. Mechanism of Action • Antiarrhythmic Drugs Act to Reduce Electrical Irregularity of the Heart by Altering the Action Potential of Cardiac Cells • All Antiarrhythmics Have the Potential to Cause Arrhythmias

  6. Mechanism of Action • Class IA Drugs Depress Rapid Depolarization (Phase 0) of the Action Potential • Class IB Drugs Exert Less Effect on Sodium Channels at Rest but Are More Prominent During Depolarization, so Their Effect on Phase 0 Is Only Slight

  7. Mechanism of Action • Class IC Drugs Markedly Depress Phase 0 and Profoundly Slow Conduction • Class II Antiarrhythmics Work by Inhibiting Sympathetic Stimulation • Class III Drugs Prolong Phase 3 Repolarization by Blocking Potassium Channels • The QT interval thus is prolonged on the ECG • Prolongation also increases the risk of torsades de pointes • Amiodarone is the exception

  8. Mechanism of Action • Class IV Drugs (Nondihydropyridine Calcium Channel Blockers) • Inhibit calcium ion influx through slow channels into conductile and contractile myocardial cells and vascular smooth muscle cells • Slow AV conduction • Prolong the effective refractory period within the AV node

  9. Mechanism of Action • Digoxin Suppresses AV Node Conduction to Increase the Effective Refractory Period and Decrease Conduction

  10. Treatment Principles • Standardized Guidelines • ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation J Am Coll Cardiol 48(4):e149-e246, 2006 • Evidence-Based Recommendations • digoxin • diltiazem • verapamil

  11. Treatment Principles • Cardinal Points of Treatment • The cardiologist determines the appropriate medication and begins treatment • Once stable, the patient may be turned over to the primary care provider for long-term monitoring

  12. Treatment Principles • Pharmacologic Treatment • Prophylaxis of PSVT • digoxin, β-blockers • verapamil • Atrial fibrillation • Control of rate • Control of rhythm • Control of thromboembolic events

  13. Treatment Principles • Pharmacologic Treatment (cont’d) • PVCs • Criteria for treatment

  14. How to Monitor • Therapeutic Effect • Toxicity • digoxin • quinidine • amiodarone

  15. Patient Variables • Geriatrics • At increased risk for adverse reactions to medications • May require decreased dosage because of possible impaired renal or hepatic function • amiodarone • Healthy subjects older than 65 years show lower clearances of amiodarone than do younger subjects, as well as an increased half-life (20 to 47 days)

  16. Patient Variables • Pediatrics • Safety and efficacy of these drugs have not been established • Pregnancy and Lactation • Category B: lidocaine • Category C: quinidine, procainamide, mexiletine, tocainide, flecainide, propafenone, propranolol, metoprolol, verapamil, diltiazem, digoxin, and adenosine • Category D: amiodarone, propranolol, metoprolol (second/third trimesters [expert opinion]), atenolol • Drugs are excreted in breast milk

  17. Patient Education • Wear a Medical Alert Bracelet and Carry a Medical Identification Card Specifying That You Are Taking an Antiarrhythmic Drug • Report Any New or Uncomfortable Symptoms to Your Health Care Provider • amiodarone • digoxin

  18. amiodarone (Cordarone) • Contraindications • Warnings/precautions • Pharmacokinetics • Adverse Effects • Drug Interactions

More Related